tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2016 Nov 7:0. [Epub ahead of print]
[h=1]Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy.[/h] Nakashima K[SUP]1[/SUP], Aoshima M[SUP]1[/SUP], Ohfuji S[SUP]2[/SUP], Suzuki K[SUP]3[/SUP], Katsurada M[SUP]1[/SUP], Katsurada N[SUP]1[/SUP], Misawa M[SUP]1[/SUP], Otsuka Y[SUP]4[/SUP], Kondo K[SUP]2[/SUP], Hirota Y[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Lung cancer is a leading cause of cancer-related death, and patients with lung cancer are a priority group for influenza vaccination. However, few studies have assessed the immunogenicity of the influenza vaccine in these patients. Here, we performed a prospective study to evaluate the immunogenicity of the influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy. Twenty-five patients with lung cancer undergoing anticancer chemotherapy and 26 patients with chronic obstructive pulmonary disease (COPD) as controls were enrolled. A trivalent influenza vaccine containing inactivated A/California/7/2009 (H1N1) pdm09, A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 was administered as a single subcutaneous injection. Serum samples were collected before vaccination, 4-6 weeks after vaccination. Levels of serum antibody to hemagglutinin were measured. Among patients with lung cancer, the seroprotection rate (postvaccination titer > 1:40) was 84% for both A(H1N1) and A(H3N2), similar to the levels observed in patients with COPD. However, the seroprotection rate for the B strain was significantly lower in patients with lung cancer than in patients with COPD (64% versus 92%). Even after adjustment for potential confounders, patients with lung cancer had a significantly lower odds ratio for seroprotection against the B strain than patients with COPD. Moreover, in patients with lung cancer, those receiving the platinum doublet treatment tended to exhibit a lower seroprotection rate than those receiving a single agent. Thus, patients with lung cancer undergoing anticancer chemotherapy showed acceptable immune responses to a trivalent influenza vaccine, supporting the recommendation for annual influenza vaccination in these patients.
[h=4]KEYWORDS:[/h] anticancer chemotherapy; chronic obstructive pulmonary disease; immunogenicity; influenza vaccine; lung cancer
PMID: 27820665 DOI: 10.1080/21645515.2016.1246094
[PubMed - as supplied by publisher]
[h=1]Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy.[/h] Nakashima K[SUP]1[/SUP], Aoshima M[SUP]1[/SUP], Ohfuji S[SUP]2[/SUP], Suzuki K[SUP]3[/SUP], Katsurada M[SUP]1[/SUP], Katsurada N[SUP]1[/SUP], Misawa M[SUP]1[/SUP], Otsuka Y[SUP]4[/SUP], Kondo K[SUP]2[/SUP], Hirota Y[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Lung cancer is a leading cause of cancer-related death, and patients with lung cancer are a priority group for influenza vaccination. However, few studies have assessed the immunogenicity of the influenza vaccine in these patients. Here, we performed a prospective study to evaluate the immunogenicity of the influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy. Twenty-five patients with lung cancer undergoing anticancer chemotherapy and 26 patients with chronic obstructive pulmonary disease (COPD) as controls were enrolled. A trivalent influenza vaccine containing inactivated A/California/7/2009 (H1N1) pdm09, A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 was administered as a single subcutaneous injection. Serum samples were collected before vaccination, 4-6 weeks after vaccination. Levels of serum antibody to hemagglutinin were measured. Among patients with lung cancer, the seroprotection rate (postvaccination titer > 1:40) was 84% for both A(H1N1) and A(H3N2), similar to the levels observed in patients with COPD. However, the seroprotection rate for the B strain was significantly lower in patients with lung cancer than in patients with COPD (64% versus 92%). Even after adjustment for potential confounders, patients with lung cancer had a significantly lower odds ratio for seroprotection against the B strain than patients with COPD. Moreover, in patients with lung cancer, those receiving the platinum doublet treatment tended to exhibit a lower seroprotection rate than those receiving a single agent. Thus, patients with lung cancer undergoing anticancer chemotherapy showed acceptable immune responses to a trivalent influenza vaccine, supporting the recommendation for annual influenza vaccination in these patients.
[h=4]KEYWORDS:[/h] anticancer chemotherapy; chronic obstructive pulmonary disease; immunogenicity; influenza vaccine; lung cancer
PMID: 27820665 DOI: 10.1080/21645515.2016.1246094
[PubMed - as supplied by publisher]